Table 4 CSC-directed immunotherapy in ongoing clinical trials
From: Targeting cancer stem cell pathways for cancer therapy
Trial description | Condition | Sample size | Phase | NCT Number | Current status |
|---|---|---|---|---|---|
CD19 CAR-T | B cell leukemia and lymphoma | II | 80 | NCT03398967 | Recruiting |
CD123 CAR-T | CD122+ myeloid malignancies | II | 45 | NCT02937103 | Recruiting |
CD22 CAR-T | Recurrent or refractory B cell malignancy | I/II | 45 | NCT02794961 | Unknown |
CD22 CAR-T | B-ALL | I | 15 | NCT02650414 | Recruiting |
CD33 CAR-T | Myeloid malignancies | I/II | 45 | NCT02958397 | Recruiting |
CD33 CAR-T | CD32+ acute myeloid leukemia | I | 11 | NCT03126864 | Active, not recruiting |
CD38 CAR-T | B-ALL | II | 80 | NCT03754764 | Recruiting |
CD138 CAR-T | Multiple myeloma | II | 10 | NCT03196414 | Recruiting |
MUC1 CAR-T/PD-1 KO | Advanced esophageal cancer | I/II | 20 | NCT03706326 | Recruiting |
EGFR IL-12 CAR-T | Metastatic colorectal cancer | I | 20 | NCT03542799 | Not yet recruiting |
MESO CAR-T | Refractory–relapsed ovarian cancer | I/II | 20 | NCT03916679 | Recruiting |
MESO-19 CAR-T | Metastatic pancreatic cancer | I | 4 | NCT02465983 | Completed |
LeY CAR-T | Myeloid malignancies | I/II | 445 | NCT02958384 | Recruiting |
MOv19-BBz CAR -T | Recurrent high-grade serous ovarian cancer | I | 18 | NCT03585764 | Recruiting |
LeY CAR-T | Advanced cancer | I | 30 | NCT03851146 | Recruiting |
EpCAM CAR-T | Recurrent breast cancer | I | 30 | NCT02915445 | Recruiting |
BCMA CAR-T | Multiple myeloma | II | 80 | NCT03767751 | Recruiting |
